Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 8;13:1094123. doi: 10.3389/fonc.2023.1094123

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Sisler, Hinz, Le, Kleczko, Nemenoff and Heasley

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

mKRC.1 tumors in C57BL/6 mice show single agent MRTX-849 response and synergistic tumor shrinkage in combination with RMC-4550. mKRC.1 cells were orthotopically implanted into the left lungs of C57BL/6 mice and allowed to establish for 14 days before initial pre-treatment μCT imaging. (A) Tumor volumes presented as fold of initial volumes (mean and SEM) from diluent, MRTX-849 (30mg/kg), RMC-4550 (30 mg/kg) and combination-treated mouse cohorts (n=4-5 per group) are shown. The arrows indicate days when treatment was initiated and terminated. The data were analyzed by 2-way ANOVA with Tukey’s multiple comparisons test. (B) Waterfall plot showing percent change in tumor volume (fold of initial) after 14 days of MRTX-849 or MRTX-849 plus RMC-4550 treatment. The data were analyzed by an un-paired t-test.